CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix platform, emables real-time multiomic insights from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.…
CelLBxHealth plc (DWV.F) Seasonal returns chart
CelLBxHealth (LON: CLBX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 114 employees.
The shares were at 0.5750 GBp on 20 November 2026, down 66.2% over 52 weeks. Its 52-week range is 0.5330 GBp to 2.800 GBp: the price is 79.5% below the high and 7.9% above the low.
Its market capitalisation is 6.53M GBP.
CelLBxHealth reports return on equity of -271.1% and revenue down 25.0% year over year.
It holds more cash than debt, a net cash position of 1.56M GBP. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.
No upcoming events tracked.